126 related articles for article (PubMed ID: 38853861)
1. Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
Sekaggya-Wiltshire C; Mbabazi I; Nabisere-Arinaitwe R; Banturaki G; Alinaitwe L; Otalo B; Aber F; Nampala J; Owor R; Bayiga J; Laker Agnes Odongpiny E; Castelnuovo B; Mayito J; Sekadde M; Pasipanodya JG; Turyahabwe S; Zawedde-Muyanja S
medRxiv; 2024 Jun; ():. PubMed ID: 38853861
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
3. Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
Lee MC; Fujita Y; Muraki S; Huang HL; Lee CH; Wang JY; Ieiri I
Br J Clin Pharmacol; 2023 Feb; 89(2):714-726. PubMed ID: 36100960
[TBL] [Abstract][Full Text] [Related]
4. Implementation of tuberculosis preventive therapy with INH-Rifapentine (3HP) for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study.
Sharma N; Bakshi R; Basu S; Zode M; Arora R; Khanna A
Trop Med Int Health; 2023 Dec; 28(12):890-900. PubMed ID: 37864386
[TBL] [Abstract][Full Text] [Related]
5. Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.
Rahman MT; Hossain F; Banu RS; Islam MS; Alam S; Faisel AJ; Salim H; Cordon O; Suarez P; Hussain H; Roy T
Trop Med Infect Dis; 2023 Dec; 9(1):. PubMed ID: 38276634
[TBL] [Abstract][Full Text] [Related]
6. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
8. Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Hussain H; Jaswal M; Farooq S; Safdar N; Madhani F; Noorani S; Shahbaz SS; Salahuddin N; Amanullah F; Khowaja S; Manzar S; Shah JA; Islam Z; Dahri AA; Shahzad M; Keshavjee S; Becerra MC; Khan AJ; Malik AA
Clin Infect Dis; 2023 Aug; 77(4):638-644. PubMed ID: 37083926
[TBL] [Abstract][Full Text] [Related]
9. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
10. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
Huang HL; Lee MR; Cheng MH; Lu PL; Huang CK; Sheu CC; Lai PC; Chen TC; Wang JY; Chong IW
Clin Infect Dis; 2021 Sep; 73(5):e1064-e1071. PubMed ID: 33215187
[TBL] [Abstract][Full Text] [Related]
11. The incorporation of the 3HP regimen for tuberculosis preventive treatment in the Brazilian health system: a secondary-database nationwide analysis.
Mendes LVP; Trajman A; Campos MR; Correa MCDV; Osorio-de-Castro CGS
Front Med (Lausanne); 2023; 10():1289298. PubMed ID: 38249969
[TBL] [Abstract][Full Text] [Related]
12. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
[TBL] [Abstract][Full Text] [Related]
13. Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
Jaswal M; Farooq S; Madhani F; Noorani S; Salahuddin N; Amanullah F; Khowaja S; Safdar N; Khan A; Yuen C; Keshavjee S; Becerra M; Hussain H; Malik AA
Int J Tuberc Lung Dis; 2022 Aug; 26(8):741-746. PubMed ID: 35898140
[No Abstract] [Full Text] [Related]
14. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
Radtke KK; Ernest JP; Zhang N; Ammerman NC; Nuermberger E; Belknap R; Boyd R; Sterling TR; Savic RM
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0170521. PubMed ID: 34606336
[TBL] [Abstract][Full Text] [Related]
15. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC; Musinguzi A; Ssemata J; Welishe F; Nabunje J; Kadota JL; Berger CA; Katamba A; Kiwanuka N; Kamya MR; Dowdy D; Cattamanchi A; Katahoire AR
Implement Sci Commun; 2021 Jun; 2(1):71. PubMed ID: 34193311
[TBL] [Abstract][Full Text] [Related]
16. Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series design.
Alvarez GG; Sullivan K; Pease C; Van Dyk D; Mallick R; Taljaard M; Grimshaw JM; Amaratunga K; Allen C; Brethour K; Mulpuru S; Pakhale S; Aaron SD; Cameron DW; Alsdurf H; Hui C; Zwerling AA
Int J Infect Dis; 2022 Apr; 117():222-229. PubMed ID: 35121126
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
[TBL] [Abstract][Full Text] [Related]
20. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Winters N; Belknap R; Benedetti A; Borisov A; Campbell JR; Chaisson RE; Chan PC; Martinson N; Nahid P; Scott NA; Sizemore E; Sterling TR; Villarino ME; Wang JY; Menzies D
Lancet Respir Med; 2023 Sep; 11(9):782-790. PubMed ID: 36966788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
